ADTnorm: robust integration of single-cell protein measurement across CITE-seq datasets.

Publication date: Jul 01, 2025

Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) enables paired measurement of surface protein and mRNA expression in single cells using antibodies conjugated to oligonucleotide tags. Due to the high copy number of surface protein molecules, sequencing antibody-derived tags (ADTs) allows for robust protein detection, improving cell-type identification. However, variability in antibody staining leads to batch effects in the ADT expression, obscuring biological variation, reducing interpretability, and obstructing cross-study analyses. Here, we present ADTnorm, a normalization and integration method designed explicitly for ADT abundance. Benchmarking against 14 existing scaling and normalization methods, we show that ADTnorm accurately aligns populations with negative- and positive-expression of surface protein markers across 13 public datasets, effectively removing technical variation across batches and improving cell-type separation. ADTnorm enables efficient integration of public CITE-seq datasets, each with unique experimental designs, paving the way for atlas-level analyses. Beyond normalization, ADTnorm includes built-in utilities to aid in automated threshold-gating as well as assessment of antibody staining quality for titration optimization and antibody panel selection. Applying ADTnorm to an antibody titration study, a published COVID-19 CITE-seq dataset, and a human hematopoietic progenitors study allowed for identifying previously undetected phenotype-associated markers, illustrating a broad utility in biological applications.

Open Access PDF

Concepts Keywords
Antibody Antibodies
Atlas Antibodies
Efficient COVID-19
Oligonucleotide Epitopes
Paving Epitopes
Gene Expression Profiling
High-Throughput Nucleotide Sequencing
Humans
Membrane Proteins
Membrane Proteins
Single-Cell Analysis
Transcriptome

Semantics

Type Source Name
disease IDO cell
disease IDO protein
disease IDO quality
disease MESH COVID-19
drug DRUGBANK Ferrous sulfate anhydrous
disease MESH aids
drug DRUGBANK Coenzyme M
drug DRUGBANK Cycloserine
drug DRUGBANK Hyaluronic acid
disease IDO process
drug DRUGBANK Esomeprazole
disease MESH anomalies
disease IDO blood
disease MESH autoimmunity
drug DRUGBANK L-Leucine
drug DRUGBANK Iron
drug DRUGBANK Tretamine
drug DRUGBANK Abacavir
drug DRUGBANK Pidolic Acid
drug DRUGBANK Gold
drug DRUGBANK Cysteamine
disease MESH leukemia
drug DRUGBANK Serine
disease MESH Arthritis
disease MESH Infection
disease IDO immunodeficiency
pathway REACTOME TCR signaling
drug DRUGBANK Rasagiline
pathway REACTOME Reproduction

Original Article

(Visited 6 times, 1 visits today)